Lansen Pharmaceutical Holdings Limited provided earnings guidance for the twelve months ended 31 December 2022. For the period, the group expected to record a net profit attributable to equity owners of approximately USD 8.1 million, representing an increase of approximately USD 7.2 million (approximately 798% increase) compared to that of last year of approximately USD 0.9 million.
Lansen Pharmaceutical Holdings Limited
Equities
503
KYG5380M1033
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+33.16% | 700B | |
-4.97% | 358B | |
+18.71% | 330B | |
+3.21% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+5.53% | 161B | |
-2.26% | 157B |